| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,078 | 0,108 | 21.01. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CIRCIO Aktie jetzt für 0€ handeln | |||||
| Fr | Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders | 2 | Oslo Børs | ||
| 15.01. | Circio Holding ASA Receipt of subscription rights in the rights issue by primary insiders and their close associates | 1 | Oslo Børs | ||
| 15.01. | Circio Holding ASA Commencement of the subscription period for the rights issue | 2 | Oslo Børs | ||
| 13.01. | Circio Holding ASA Approval and publication of prospectus for the rights issue | 2 | Oslo Børs | ||
| 13.01. | Circio Holding ASA Ex. subscription rights today | 1 | Oslo Børs | ||
| 12.01. | Circio Holding ASA: Circio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue | 1 | Oslo Børs | ||
| 12.01. | Circio Holding ASA Extraordinary general meeting held, all agenda items approved | 1 | Oslo Børs | ||
| 12.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.01.2026 | 675 | Xetra Newsboard | Das Instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG KG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 12.01.2026 und ex Kapitalmassnahme am 13.01.2026 The instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG... ► Artikel lesen | |
| 09.01. | Circio Holding ASA Updated key information relating to the rights issue | 1 | Oslo Børs | ||
| 23.12.25 | Circio Holding ASA Updated information to the notice of extraordinary general meeting 2026 | 1 | Oslo Børs | ||
| 19.12.25 | Circio Holding ASA Notice of extraordinary general meeting on 12 January 2026 | 1 | Oslo Børs | ||
| 08.12.25 | Circio Holding ASA Key information related to the rights issue | 3 | Oslo Børs | ||
| 08.12.25 | Circio Holding ASA: Circio announces 88% underwritten and presubscribed NOK 50 million rights issue with strong support from existing shareholders | 2 | Oslo Børs | ||
| 03.12.25 | Circio Holding ASA: Corr*: Atlas Holdings for CIRCIO | 2 | Oslo Børs | ||
| 03.12.25 | Circio Holding ASA: Atlas Holdings for CIRCIO | 8 | Oslo Børs | ||
| 24.11.25 | Circio Holding ASA: Circio presents data that further strengthens and broadens its circVec circular RNA expression platform | 2 | Oslo Børs | ||
| 19.11.25 | Circio Holding ASA: Atlas Holdings for CIRCIO | - | Oslo Børs | ||
| 19.11.25 | Circio Holding ASA: Shareholding Disclosure - Nordnet | 1 | Oslo Børs | ||
| 18.11.25 | Circio Holding ASA: Shareholding disclosure - Nordnet AB | 1 | Oslo Børs | ||
| 17.11.25 | Circio Holding ASA: Circio issues invitation to R&D and corporate update webcast on 24 November 2025 | 2 | Oslo Børs |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | -3,65 % | Schlägt Thermo Fisher zu?: Qiagen: Übernahmegerüchte schicken die Aktie auf Kursachterbahn | © Foto: Rafael Henrique - picture allianceÜbernahmegerüchte um den Diagnostikspezialisten Qiagen sorgten am Dienstag für einen rekordverdächtigen Kursanstieg. Am Mittwoch kommt die Aktie wieder etwas... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| BIONTECH | 100,90 | -0,10 % | Biontech-Konkurrent Moderna im Aufwind: Ist das die Wende? | Die Aktien des Biontech-Rivalen Moderna setzen ihren Aufwärtstrend fort. Am Vormittag steigen sie um drei Prozent, nachdem sie gestern im US Handel zeitweise um 17 Prozent nach oben geschnellt waren.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals beruft neuen COO und Chief Strategy Officer | ||
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 40 US-Dollar | ||
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung |